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Aim We assessed the management and outcomes of non-ST segment elevation myocardial infarction (NSTEMI)
patients randomly assigned to fractional flow reserve (FFR)-guided management or angiography-guided standard
care.
Methods
and results
We conducted a prospective, multicentre, parallel group, 1 : 1 randomized, controlled trial in 350NSTEMI patients with
≥1 coronary stenosis≥30%of the lumendiameter assessed visually (threshold for FFRmeasurement) (NCT01764334).
Enrolment took place in six UK hospitals fromOctober 2011 to May 2013. Fractional flow reserve was disclosed to the
operator in the FFR-guided group (n ¼ 176). Fractional flow reservewasmeasured but not disclosed in the angiography-
guided group (n ¼ 174). Fractional flow reserve≤0.80was an indication for revascularization by percutaneous coronary
intervention (PCI) or coronary artery bypass surgery (CABG). The median (IQR) time from the index episode of myo-
cardial ischaemia to angiographywas 3 (2, 5) days. For the primary outcome, the proportion of patients treated initially by
medical therapy was higher in the FFR-guided group than in the angiography-guided group [40 (22.7%) vs. 23 (13.2%),
difference 95% (95% CI: 1.4%, 17.7%), P ¼ 0.022]. Fractional flow reserve disclosure resulted in a change in treatment
between medical therapy, PCI or CABG in 38 (21.6%) patients. At 12 months, revascularization remained lower in
the FFR-guided group [79.0 vs. 86.8%, difference 7.8% (20.2%, 15.8%), P ¼ 0.054]. Therewere no statistically significant
differences in health outcomes and quality of life between the groups.
Conclusion In NSTEMI patients, angiography-guided management was associated with higher rates of coronary revascularization
compared with FFR-guided management. A larger trial is necessary to assess health outcomes and cost-effectiveness.
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Introduction
Non-ST segment elevation myocardial infarction (NSTEMI) is the
commonest form of acute coronary syndrome (ACS), the most
common indication for invasive coronary angiography, and a leading
global cause of prematuremorbidity andmortality.1 Coronary angiog-
raphy in ACS patients can detect obstructive coronary artery disease
and identify patients who may benefit from coronary revasculariza-
tion.1–3 Usual care is based on visual interpretation of coronary
disease severity and management decisions include medical therapy,
percutaneous coronary intervention (PCI) or coronary artery bypass
surgery (CABG). Visual assessment of lesion severity with coronary
angiography may be inaccurate resulting in over- or underestimation
of the physiological significance of the lesion.4,5 Hence judgements
made by cardiologists in every day practice are subjective, potentially
leading to misdiagnosis and incorrect treatment decisions.4–6
An alternative approach involves themeasurement of themyocar-
dial fractional flow reserve (FFR) using a pressure-sensitive coronary
guidewire. Fractional flow reserve assesses the physiological sig-
nificance of a coronary stenosis and is expressed as the ratio of
maximal blood flow in a stenotic artery to maximal flow in an unob-
structed artery.7 Recent studies (DEFER,8 FAME,9 FAME-2,10 and
RIPCORD11) have evaluated the value of FFR to guide treatment
decisions.AnFFR≤0.80 is anevidence-basedphysiological threshold
that correlates with the presence of inducible ischaemia on non-
invasive testing.7 Fractional flow reserve values .0.80 indicate that
patients can be managed safely with medical therapy without the
need for coronary revascularization.
Fractional flow reserve measurements require maximal coronary
hyperaemiawhichmay be less readily achieved in patients with acute
coronary disease because of coronary microvascular dysfunc-
tion.12,13 Recent clinical studies indicate that FFR in this setting may
be valid14–18 but in the absence of evidence from randomized pro-
spective trials, a routine physiological approach for the management
of patients with recent MI is not recommended in guidelines.1–3We
hypothesized that management decisions in patients with NSTEMI
undergoing coronary angiography guided by routine FFR measure-
ment would be feasible and safe, and would provide additive clinical
utility comparedwith standard care based on visual interpretation of
the angiogram.
Methods
Trial design
We performed a prospective 1 : 1 randomized controlled parallel group
trial in 350NSTEMI patients enrolled fromOctober 2011 toMay 2013.19
Participants and eligibility criteria
Patients with a clinical diagnosis of recent NSTEMI1 and with at least one
risk factor for coronary artery disease (e.g. diabetes mellitus) were
eligible for randomization if urgent invasive management was planned
within 72 h of the index episode of myocardial ischaemia or if there
was a history of recurrent ischaemic symptoms within 5 days. The angio-
graphic inclusion criteria required at least one coronary stenosis ≥30%
severity with normal coronary blood flow [Thrombolysis in Myocardial
Infarction (TIMI) grade III] in which FFR measurement might have a diag-
nostic value.
The exclusion criteria were the presence of ischaemic symptoms that
were not controlled by medical therapy, haemodynamic instability, MI
with persistent ST elevation, intolerance to anti-platelet drugs, ineligible
for coronary revascularization, a treatment plan for non-coronary heart
surgery (e.g. valve surgery), a history of prior CABG, angiographic evi-
denceof severe (e.g. diffuse calcification)ormild (,30%severity) coron-
ary disease, a life expectancy ,1 year and an inability to give informed
consent.
Setting
The study participants were enrolled in six hospitals in the UK, of which
threewerenon-academic regional centres, and theirmedical and invasive
management followed evidence-based guidelines, including complete
revascularization during the index hospitalization, as appropriate.1–3
Informed consent
The study information sheet that had been approved by the research
ethics committee was provided to each participant. Written informed
consentwasobtained before the diagnostic coronary angiogramand ran-
domization.
Coronary angiogram acquisition and analyses
Coronary angiograms were acquired during usual care with standard
cardiac catheter laboratory equipment. The angiograms were assessed
visually by the attending clinicians who made the treatment decision
for medical therapy, PCI or CABG.
Randomization, implementation, and blinding
Participantswere enrolled by research staff on thewardbefore the angio-
gram was obtained. The standard care management strategy was estab-
lished and recorded before FFR was measured. The treatment plan was
based on all of the clinical information including the results of the angio-
gram and before FFR was measured. If the angiographic eligibility criteria
were fulfilled, thepatientswere then randomizedby the researchnurse in
the catheter laboratory to FFR-guided and angiography-guided strategies
using a web-based randomization system. The randomization sequence
was created using randomized permuted blocks of length 4, without
stratification. The allocation sequence was on a 1 : 1 basis between the
FFR-guided group and the angiography-guided group and the sequence
was concealed electronically. The participants were blinded to the treat-
ment group allocation.
Interventions
The randomized participants had FFR measured in all coronary arteries
with a lesion of ≥30% diameter stenosis that were amenable to instru-
mentation with a pressure-sensitive coronary guidewire (St Jude
Medical, Uppsala).19 Fractional flow reserve was measured during
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coronary hyperaemia inducedby i.v. adenosine (140 mg/kg/min). The FFR
intervention in this study, including the assessment of adenosine effect,
the measurement of FFR, vessel selection, blinding and disclosure of
the FFR results, has been previously described.19
Fractional flow reserve-guided group
Fractional flow reserve ≤0.80 was an indication for revascularization by
PCI or CABG, as appropriate, and FFR .0.80 was an indication for
medical therapy only. Any changes in management strategy following
FFR disclosure were prospectively recorded.
Angiography-guided group and blinding
In patients randomized to the angiography-guided group, FFR was mea-
sured in the same way as in the FFR-guided group except that the FFR
results were not disclosed. The research staff obscured the haemo-
dynamic monitor [RadiAnalyzer Xpress (St Jude Medical, Uppsala)]
from the clinicians, nurses, and patients such that it was impossible for
them to observe the pressure wire information either in the catheter
laboratory or afterwards. Electronic displays of distal coronary pressure
on other haemodynamicmonitors thatmay have been visible in the cath-
eter laboratory were also disabled. Quality control checks, including
assessments of equalized pressure recordings and verification of symp-
toms and haemodynamic changes with i.v. adenosine, were conducted
in the usual way. The quality assurance procedures have been previously
described.19
Outcomes
Primary outcome
Thepre-specifiedprimaryoutcomewas the between-groupdifference in
the proportion of patients allocated to medical management. The final
treatment decision was made by the clinicians in the cardiac catheter la-
boratory during the index procedure or shortly afterwards if a multidis-
ciplinary heart team review was indicated.
Secondary outcomes
(1) The feasibility and safety of routine FFR measurement.
(2) The relationship between FFR and coronary stenosis severity by
visual assessment of the angiogram.
(3) Major adverse cardiac events (MACE) during the follow-up over 12
months, defined as cardiac death20 or hospitalization for myocardial
infarction21 or heart failure20 after randomization. Cardiovascular
death, stroke, transient ischaemic attack, contrast nephropathy,
and bleeding were also prospectively recorded.20 All of these
events were adjudicated by a Clinical Event Committee (CEC) com-
prised of three cardiologists who were independent of the trial and
blinded to the treatment allocations. The CEC charter and the defi-
nitions for these events are described in the Supplementary material
online,Methods.19–23 Coronary revascularization, including PCI and
CABG, were prospectively recorded in the clinical report form.
Information on serious adverse events during the follow-up was
obtained by contacting the patients by telephone and reviewing
their primary and secondary care records. All complications that
werepotentially related to the invasiveprocedurewereprospective-
ly recorded.
(4) Index hospitalization resource use including: material, procedure,
hospitalization, and in-hospital event costs.
(5) Health-related quality of life [HRQoL; EuroQol 5-Dimensions
3-Level (EQ-5D-3L)].24
Healthcare resources and costs
Costs during index hospitalization were calculated by applying resource
use or events at the individual level to unit costs derived from NHS
National Procurement,25 NHS Reference Costs,26 Information Services
Division Scotland,27 the British National Formulary (www.bnf.org), and
the Golden Jubilee National Hospital. Further details of the methods
are provided in the Supplementary material online,Methods.
Trial management
The trialwas conducted in linewithGuidelines forGoodClinical Practice
in Clinical Trials,28 and the study complies with the Declaration of Hel-
sinki. Therewas aTrialManagementGroup foroperational activity, an in-
dependent Clinical Event Committee to adjudicate on serious adverse
events for safety and efficacy outcomes, an independent Data and
Safety Monitoring Committee (DSMC),29 and a Trial Steering Commit-
tee to coordinate the trial and liaise with the Sponsor and Trials Unit
(Supplementary material online, Methods). During the course of the
trial, the DSMC met once and received two safety and progress
reports from the trials unit (June 2012 and March 2013).
The Robertson Centre for Biostatistics within the Glasgow Clinical
Trials Unit provided the trial-specific electronic data collection system,
acted as an independent coordinating centre for randomization and
data management, and conducted the statistical analyses. The trial was
approved by the National Research Ethics Service (reference 11/S0703/6).
The clinical trial registration numbers are NCT01764334 and
ISRCTN97489534 and the trial sponsor is the National Waiting Times
Centre Board, NHS Scotland. The sponsor monitored the study for
safety and the study underwent an external audit commissioned by the
sponsor (October 2013). All serious adverse events were prospectively
reported to the Robertson Centre for Biostatistics.
Sample size
Wecalculated that 322 randomized subjects (161 subjects in each group)
would provide 90% power at a 5% level of significance to detect a 50%
relative increase in the proportion of patients assigned to medical treat-
ment in the FFR disclosed group from 15 to 30%. This difference was
based on observations made in a pilot study30 intended to inform the
design of the current trial. Allowing for loss of data at the time of the pro-
cedure the number of participants in the randomized trial was increased
to 350.
Statistical methods
Mean (standard deviation) ormedian (inter-quartile range) were used to
summarize continuous data. Counts and percentages were used to sum-
marize categorical data. All tests were two-tailed and assessed at the 5%
significance level.
The primary outcome of the proportion of patients allocated to
medical therapy was assessed in terms of the difference in proportions
and the relative risk between groups estimated with exact 95% confi-
dence intervals and P-values. The proportion of patients with MACEs
within 12 months and other binary outcomes were analysed using the
same methods, and time to events within 12 months was compared
between groups using log-rank tests. Health-related quality of life was
compared between groups using baseline-adjusted linear regression.
Length of stay was compared between groups using a Wilcoxon-Rank
Sum test. Costs were compared using bootstrapping (details in Supple-
mentary material online, Methods). The statistical analyses were per-
formed using R version 3.0.0 and StatXact version 5.0.3.
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Results
Eight hundred and fifty-three NSTEMI patients were referred for in-
vasive management and gave informed consent from October 2011
to May 2013 (Figure 1 ; Table 1). Of these, 350 patients (mean age 62
years, 74% male) were randomized (n ¼ 176 FFR-guided, n ¼ 174
angiography-guided). Fractional flow reserve was measured in all
(100%) participants but only disclosed in the FFR-guided group.
Figure 1 Flow diagram of the clinical trial.
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Table 1 Baseline clinical and angiographic characteristics of all-comers
Baseline characteristicsa Randomly assigned groups
FFR-guided group
n 5 176
Angiography-guided group
n5 174
Clinical
Age, years 62.3 (11.0) 61.6 (11.1)
Male sex, n (%) 133 (75.6) 127 (73.0)
Heart rate, b.p.m. 73 (15) 74 (17)
ECG evidence of ischaemia at initial presentation, n (%) 137 (77.8) 143 (82.2)
Peak troponin concentration before the procedurea
.×5 upper limit of normal 129 (73.3) 137 (78.7)
.×10 upper limit of normal 107 (60.8) 115 (66.1)
GRACE score for death or myocardial infarction within 6 months of admission 146 (131, 173) 146 (122, 172)
Patients with a GRACE score for death or myocardial infarction within 6 months .140, n (%) 102 (58.0) 97 (55.7)
Diabetes mellitusb, n (%) 26 (14.8) 26 (14.9)
History of atrial fibrillation or flutter, n (%) 12 (6.8) 7 (4.0)
History of stroke or transient ischaemic attackb, n (%) 15 (8.5) 9 (5.2)
History of peripheral vascular diseaseb, n (%) 14 (8.0) 14 (8.0)
Previous myocardial infarction, n (%) 22 (12.5) 24 (13.8)
Previous percutaneous coronary intervention, n (%) 19 (10.8) 19 (10.9)
History of treated hypertensionb, n (%) 78 (44.3) 81 (46.6)
History of treated hypercholesterolaemiab, n (%) 71 (40.3) 56 (32.2)
History of smokingb, n (%)
Current 72 (40.9) 71 (40.8)
Former (stopped .3 months) 55 (31.2) 47 (27.0)
Never 49 (27.8) 56 (32.2)
Angina, Canadian Cardiovascular Society angina class at presentation, n (%)
I 1 (0.6) 0 (0)
II 1 (0.6) 2 (1.1)
III 7 (4.0) 15 (8.6)
IV 166 (94.3) 156 (89.7)
New York Heart Association functional class at presentation, n (%)
I 154 (87.5) 154 (88.5)
II 17 (9.7) 16 (9.2)
III 2 (1.1) 3 (1.7)
IV 3 (1.7) 1 (0.6)
Frailty, n (%)a
Well 148 (87.1) 144 (87.8)
Vulnerable 20 (11.8) 17 (10.4)
Frail 2 (1.2) 3 (1.8)
Health-related quality of life, EQ-5D score 0.78 (0.29) 0.81 (0.25)
Medication at procedure
Aspirin, n (%) 175 (99.4) 173 (99.4)
P2Y12 inhibitor, n (%) 176 (100) 173 (99.4)
Clopidogrel 169 (96.0) 168 (97.1)
Ticagrelor or Prasugrel 7 (4.0) 5 (2.9)
Statin, n (%) 168 (95.5) 167 (96.0)
Beta-blocker, n (%) 161 (91.5) 147 (84.5)
Calcium channel blocker, n (%) 27 (15.4) 25 (14.4)
Isosorbide mononitrate, n (%) 18 (10.2) 20 (11.5)
Continued
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The clinical and treatment characteristics of the patients included in
the FFR-guided group and the angiography-guided groupwere similar
(Table 1).
Three hundred and twenty-two (92%) of 350 randomized partici-
pants had a historyof angina at rest (CanadianCardiovascular Society
Angina Class IV angina) and 280 (80%) patients had ECG evidence of
ischaemia. The median (inter-quartile range) time from the index
episode of myocardial ischaemia to the invasive angiogram was 3
(2, 5) days and 81% of the participants underwent angiography
within 5 days of the index event or most recent episode of chest
pain. All the patients were followed up for 12 months and all of the
randomized participants were included in the analysis.
Fractional flow reserve-guided vs.
Angiography-guided treatment groups
Fractional flow reserve was measured in 704 (99.7%) of 706 lesions
with a stenosis severity ≥30%, and was measured in at least one
artery in all (100%) patients. Of lesions with an FFR result (n ¼ 704),
430 (61.1%) were physiologically significant (FFR ≤0.80) (Table 2
and Supplementary material online).
Ten participants (2.9%) had no lesions (stenosis severity ,50%)
when assessed by angiography and 63 (18.0%) patients had no
lesions when subsequently assessed by FFR (.0.80). The number
of patients with 0, 1, 2, or ≥3 vessel coronary disease is shown in
Supplementary material online, Figure S1.
Primary outcome
The proportion of patients treated by medical therapy was higher in
theFFR-guidedgroupthan in theangiography-guidedgroup[40 (22.7%)
vs. 23 (13.2%), difference 9.5% (95% CI: 1.4%, 17.7%), P ¼ 0.022; rela-
tive risk 1.72 (1.08, 2.82)] (Table 3).
The initial treatment decisions before randomization and after FFR
disclosure in the FFR-guided group are shown in Figure 2. Fractional
flow reserve-disclosure resulted in a change in treatment plan in 38
(21.6%) of 176 patients. The relationship between FFR and stenosis
severity is shown in Figure 3.
Resource use and material costs during
the index hospitalization
The duration of the index invasive procedure, the volume of radio-
graphic contrast medium, and the number, type (drug-eluting stent
vs. baremetal stent) and lengthof stentswere similar in the FFR-guided
group and angiography-guided groups (Table 3). Mean material costs
were higher in the FFR-guided group (£1095, 95% confidence interval
£1021 to£1171) comparedwith the angiography-guided group (£822,
95% confidence interval £737 to £914). Mean in-hospital healthcare
costs were similar in the FFR-guided group (£7289, 95% confidence
interval £6173 to £8549) and the angiography-guided group (£7484,
95% confidence interval £6325 to £8777) (Table 3).
Clinical events and safety
In-hospital adverse events relating to procedure safety are described
in Table 3. According to independent adjudication based on review
of the coronary angiograms, 8 coronary artery dissections occurred
in 7 (2.0%)of 350patientsduring the indexprocedure. Six dissections
were attributed to coronary instrumentation during PCI and 2 were
attributed to the pressure wire.
The follow-up assessments were completed in June 2014. Vital
status at 12 months was obtained for all (100%) participants
(Table 3). Fourteen (8.0%) of 176 patients in the FFR-guided group
and 15 (8.6%) of 174 in the angiography-guided group experienced
cardiac death, non-fatal myocardial infarction or heart failure hospi-
talization (P ¼ 0.89) (Table 3; Figure 4). Myocardial infarction relating
to PCI (Type 4a or Type 4b) or CABG (Type 5) occurred in 5 (2.8%)
patients in the FFR-guided group and 11 (6.3%) patients in the
angiography-guided group (P ¼ 0.12) (Table 3). Major adverse
cardiac events excluding MI related to revascularization occurred
in 10 (5.7%) patients in the FFR-guided group and 5 (2.9%) patients
in the angiography-guided group (P ¼ 0.25) (Table 3; Supplementary
material online, Figure S3).
Health outcomes in patients treated initially with
medical therapy alone
Sixty three (18.0%) of 350 randomized participants were initially
managed medically without revascularization. Of these, 3/40 (7.5%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 1 Continued
Baseline characteristicsa Randomly assigned groups
FFR-guided group
n 5 176
Angiography-guided group
n5 174
Nicorandil, n (%) 18 (10.2) 13 (7.5)
Intravenous nitrate, n (%) 32 (18.2) 21 (12.1)
Low molecular weight heparin, n (%) 165 (93.8) 168 (96.6)
ECG, electrocardiogram.
Means+ SDormedian (inter-quartile range) for normal andnon-normally distributeddata, respectively.Categories for peak troponin I andTconcentrationsweredetermined based
on the upper limit of normal (99th centile) for each hospital.
aIn the Registry, the mean age was 63.8 (12.3) years and 328 (65.3%) were male.
bAt least one risk factor for coronary artery disease was required for eligibility. Diabetes mellitus was defined as a history of diet-controlled or treated diabetes. Frailty was assessed
using the frailty index score (Supplementary material online, Methods31) and the six categories were summarized into three groups: well, vulnerable, or frail.
Data for the randomized participants were missing for the following variables: frailty index,31 n ¼ 6 patients in the FFR-guided group and n ¼ 10 patients in the angiography-guided
group.
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Table 2 Procedure characteristics and findings
Characteristicsa Randomly assigned groups
FFR-guided
group
n 5 176
Angiography-guided
group
n 5 174
Procedure
Time from index episode of myocardial ischaemia to the invasive angiogram, days 3 (1, 4) 4 (2, 5)
Procedure characteristics
Radial artery access, n (%) 158 (89.8) 157 (90.2)
Procedure time (including angiography and PCI), min 66.5 (23.4) 70.5 (33.5)
Volume of contrast used, mL 218.7 (97.3) 221.9 (110.4)
Stents
Number of stents per patient 1.1 (1.1) 1.4 (1.2)
Total stent length per patient, mm 24.4 (24.7) 29.4 (26.9)
Total number of stents 203 245
Angiographic findings
Total number of lesions with a stenosis ≥30% of the reference diameter of the artery 355 351
Total numberof lesionswith a stenosis≥50%of the referencediameterof theartery (%of all lesions) 331 (93.2) 314 (89.5)
Patients with at least one lesion ≥50% severity, n (%) 172 (97.7) 168 (96.6)
Arteries with at least one angiographically significant lesion, n (%)
0 4 (2.3) 6 (3.4)
1 62 (35.2) 68 (39.1)
2 72 (40.9) 69 (39.7)
3 33 (18.8) 27 (15.5)
4 5 (2.8) 4 (2.3)
Patients with at least one lesion ≥50% severity in the proximal or mid left anterior
descending artery, n (%)
115 (65.3) 110 (63.2)
Patients with at least one lesion ≥50% severity in the left main artery, n (%) 2 (1.1) 6 (3.4)
FFR findings
Lesions successfully measured for FFR, number/total number (%) 355 (100) 349 (99.4)
Number of physiologically significant (FFR ≤0.80) lesions (% of all lesions) 208 (58.6) 222 (63.6)
Arteries with at least one physiologically significant (FFR ≤0.80) lesion, n (%)
0 34 (19.3) 29 (16.7)
1 91 (51.7) 90 (51.7)
2 39 (22.2) 42 (24.1)
≥3 12 (6.8) 13 (7.5)
Patients with at least one physiologically significant lesion (FFR ≤0.80), n (%) 142 (80.7) 145 (83.3)
Patients with at least one physiologically significant lesion (FFR ≤0.80) in the proximal or
middle left anterior descending artery, n (%)
72 (40.9) 86 (49.4)
Mean FFR in lesions with FFR ≤ 0.80 0.56 (0.12) 0.58 (0.13)
Lesion characteristics based on visual interpretation of the angiogram
Stenosis, n (%)
30–49% of diameter 24 (6.8) 37 (10.5)
50–69% of diameter 76 (21.4) 73 (20.8)
70–89% of diameter 113 (31.8) 88 (25.1)
≥90% of diameter 111 (31.3) 124 (35.3)
Total occlusion 31 (8.7) 29 (8.3)
TIMI, thrombolysis in myocardial infarction grade.
A diseased artery was defined as an epicardial artery with one or more lesions ≥30% of the reference vessel diameter and amenable to PCI or CABG. An angiographically significant
artery was defined as an artery with one or more lesions ≥50% of the reference vessel diameter.
aMean+ SD or median (inter-quartile range) for normal and non-normally distributed data, respectively.
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in the FFR-guided group had aMACEevent during 12 months follow-
up vs. 0/23 (0%) in the angiography-guided group (P ¼ 0.22; Supple-
mentary material online, Table S2).
Revascularization within 12 months
Compared with the angiography-guided group, the percentage of
patients who were free from coronary revascularization remained
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Table 3 Primary and secondary outcomes and procedure characteristics
Outcomea Randomly assigned groups Risk difference
(95% CI)
P-valueb
FFR-disclosure
group
n 5 176
Angiography
group
n 5 174
Primary outcome
c
Medical management, n (%) 40 (22.7) 23 (13.2) 9.5% (1.4, 17.7%) 0.022
Coronary revascularization during the index admission 136 (77.3) 151 (86.8)
Percutaneous coronary intervention, n (%) 125 (71.0) 139 (79.9) 28.9% (218.1, 0.2%) 0.057
Coronary artery bypass graft, n (%) 11 (6.2) 12 (6.9) 20.7% (26.2, 4.8%) 0.87
In-hospital adverse events
Contrast nephropathy 2 (1.1) 1 (0.6) 0.6% (22.2, 3.5%) 0.69
Major bleeding 2 (1.1) 1 (0.6) 0.6% (22.2, 3.5%) 0.69
Health outcomes at 12 months, n (%)
Cardiovascular death, non-fatal myocardial infarction, unplanned
hospitalization for stroke or transient ischaemic attack
(MACCE)
13 (7.4) 16 (9.2) 21.8% (27.9, 4.2%) 0.56
Cardiac death, non-fatal myocardial infarction or unplanned
hospitalization for heart failure (MACE)
14 (8.0) 15 (8.6) 20.7% (26.7, 5.3%) 0.89
MACE, excluding procedure-related myocardial infarctiond 10 (5.7) 5 (2.9) 2.8% (21.6, 7.6%) 0.25
All-cause death 5 (2.8) 3 (1.7) 1.1% (22.4, 5.0%) 0.54
Fatal or non-fatal myocardial infarctiond 11 (6.2) 15 (8.6) 22.4% (28.2, 3.3%) 0.49
Myocardial infarction related to coronary revascularization
(Type 4a, Type 4b and Type 5 myocardial infarction)
5 (2.8) 11 (6.3) 23.5% (28.5, 1.1%) 0.12
Spontaneous myocardial infarction 7 (4.0) 5 (2.9) 1.1% (23.1, 5.5%) 0.69
Heart failure 1 (0.6) 0 (0.0) 0.6% (21.6, 3.2%) 0.51
Stroke or TIA 0 (0.0) 1 (0.6) 20.6% (23.2, 1.5%) 0.52
Other secondary outcomes Mean difference (95% CI) P-value
Health-related quality of life: EQ-5D health status at 12 months 0.844 (0.236) 0.804 (0.284)
Change from baseline health status at 12 months 0.066 (0.357) 20.010 (0.276) 0.055 (20.010, 0.120) 0.095
Cost through index hospitalization, mean (SE) £ 7289 (608) 7484 (632) 2194 (2961 to 575) 0.61
Material cost, mean (SE) £e 1095 (39) 822 (46) 274 (157 to 389) ,0.01
Procedure cost, mean (SE) £e 467 (111) 502 (118) 235 (2307 to 227) 0.78
Hospitalization cost, mean (SE) £e 5701 (585) 6117 (611) 2415 (21069 to 239) 0.21
In-hospital event cost, mean (SE) £e 25 (19) 43 (19) 218 (269 to 37) 0.46
Duration of hospital stay at baseline admission, days 6.1 (3.3) 6.5 (3.1) 20.44 (29.41 to 8.51) 0.09
FFR, fractional flow reserve.
aMeans+ SD and median (interquartile range) are used for normal and non-normally distributed data. Cost data are reported as mean+ SE.
bFFRwasmeasured in all participants and disclosed in the FFR-guided groupbut not disclosed in the angiography-guided group. The P-value is the comparison between the FFR-guided
group and angiography-guided group.
cThe index treatment decision as per randomized strategy occurred in 171 (97.2%) of the participants in the FFR-guided group and 173 (99.4%) of the participants in the
angiography-guided group.
dOf the10patientswith spontaneousMACE in theFFRgroup, FFRdisclosure changed the initial treatmentplan fromPCI tomedical therapy for the culprit artery in fourpatients. These
events happened from3 to11months after randomization. The excessof fivepatientswith a spontaneousMACE in the FFR group is due to twodeaths, twopatientswith spontaneous
MI and one patient with a heart failure hospitalization.Myocardial infarction: 28 non-fatal MI events and 2 fatal MI events occurred within 12 months of randomization in 26 patients,
including 17 procedure-relatedMIs in 16 patients [one standard carepatient had twoprocedure-relatedMIs (indexprocedureand a subsequent procedure during the follow-up)] and
11 spontaneousMIs in 10 patients (one FFR patient had twoof these events)]. Twenty-six patients had at least oneMI event. Four patients had twoMI events (n ¼ 2 FFR-guided group,
n ¼ 2 angiography-guided group). In summary, one patient had two procedure-related MIs, one patient had two spontaneous MIs and two patients had both types of MI.
eMaterial costs includes: guide catheters, ordinary guidewires, pressure wires, adenosine, balloon catheters, drug-eluting stents, bare metal stents, GP inhibitors, and bivalirudin;
Procedure costs includes: CABG, intravascular ultrasound, optical coherence tomography, echocardiogramand chestX-ray; hospitalization costs includes catheterization laboratory
time, CCU days, ITU days and general ward days; in-hospital events included MI and stroke.
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higher in the FFR disclosure group at 12 months [37 (21.0%) vs. 23
(13.2%), difference 7.8% (20.2%, 15.8%), P ¼ 0.054; relative risk
1.59 (0.99, 2.62)] (Supplementary material online, Table S3).
Health-related quality of life
Health-related quality of life scores were similar in each group at 12
months (Table 2).
Discussion
In this trial, we assessed a routine physiological approach combined
with coronary angiography to diagnose and treat coronary artery
disease in patients with recentNSTEMI undergoing invasivemanage-
ment.
Comparedwith an anatomical approach based on visual interpret-
ation of the coronary angiogram (standard care), FFR-guided
management was feasible and safe in the catheter laboratory. The
FFR-guided approach resulted in changes in stenosis classification
and patient management in one-fifth of the patients. The rate of cor-
onary revascularization was reduced at the index procedure and
most of this difference was maintained at 12 months. Material costs
during the indexprocedure increasedbecauseof the costof thepres-
surewirebutoverall healthcare costsduring the indexhospitalization
were similar. Myocardial infarction related to revascularization
tended to be more frequent in the standard care group, whereas
MACE events unrelated to revascularization tended to be more
common in the FFR group. There was no evidence for differences
in the other health outcomes or in health-related quality of life
between the randomized groups.
The results of this trial have several implications. Firstly, routine
FFR measurement in appropriately selected NSTEMI patients was
feasible in all of the participants and relatively safe. Radial artery
accesswas thenormandbleeding complicationswere rare. Secondly,
on an individual patient basis, FFR disclosure commonly changed
patient management (Figure 2), and overall, revascularization was
reduced. Thirdly, compared with the angiography-guided group,
the increased adoption ofmedical therapy at the expense of revascu-
larization in the FFR disclosure group was associated with similar
overall health outcomes and quality of life at 1 year. Representing a
balance of competing risks, the reduction in procedure-related MI
events in the FFR group should be considered against the increase
in spontaneous cardiac events during the follow-up. Finally, based
on the combination of coronary angiography and the use of FFR,
the diagnostic work-up of patients admitted with NSTEMI could be
simplified ruling out the need for deferred management and non-
invasive stress testing in NSTEMI patients with a broad range of sten-
osis severities (≥30%).
In invasively managed NSTEMI patients, the standard care
approach involves visual interpretation of the anatomical severity
of disease disclosed by the coronary angiogram. Adoption of a
Figure 3 Relationship between angiographic stenosis severity
assessed visually before randomization and fractional flow reserve.
Figure 2 Fractional flow reserve-guided group: treatment deci-
sions initially based on angiography alone and then finally after frac-
tional flow reserve disclosure.
Figure 4 Kaplan–Meier plots for major adverse cardiac events
during12-month follow-up in theFFR-guidedgroupandangiography-
guided group.
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physiological approach to inform treatment decisions in invasively
managed NSTEMI patients is not the standard of care mainly
because of a lack of evidence. The specific uncertainties for FFR adop-
tion relate to a lack of evidence for FFR measurement in culprit arter-
ies.1–3Whencoronary resistance is reducedbyvasodilatordrugs, such
as adenosine, the curvilinear relationship between coronary pressure
and flow becomes approximately linear in the physiological range of
blood pressure.32,33 Following STEMI, vascular injury may limit micro-
vascular vasodilatation12 and this may limit the validity of FFR which is
by definition a hyperaemic index. In NSTEMI, the pathophysiology of
the culprit artery is typically non-occlusive thrombotic plaque
rupture and subendocardial infarction.34 Since FFR was measured in
coronary arteries with normal blood flow, microvascular dysfunction
may have been limited, transient or absent in the participants in this
trial.18 The post hoc analysis of medically stabilized ACS patients in
the FAME trial also supports the validity of FFR.17
A further area of uncertainty that was addressed in this trial relates
to themanagement of NSTEMI patients with non-obstructive culprit
lesions and potentially rupture-pronenon-culprit lesions. Stenting to
seal a non-flow limiting ruptured coronary plaque might reduce the
risk of recurrent MI. Alternatively, optimal medical therapy might
suffice and unnecessary stenting can be harmful (e.g. stent throm-
bosis, restenosis). The likelihood ofMI increaseswith coronary sten-
osis severity and revascularization guided by FFR reduces this risk in
stable patients.7–10Whether FFR-guided management has prognos-
tic benefits inACSpatients is uncertain and controversial.On theone
hand, a reduction in revascularizationmay reduce procedure-related
MI. On the other hand, the risk of spontaneous MI might increase in
the longer-term in non-revascularized patients since plaque with
rupture-prone biology may be non-flow limiting (FFR .0.80). In
our trial, 4 of the 10 patients with spontaneous MACE in the FFR
group had an initial treatment plan for PCI in a culprit artery
changed to medical therapy based on an FFR .0.80. The spontan-
eousMACEevents in these patientsoccurred later during the follow-
up (3–11 months) in keeping with remodelling in the culprit artery
and late spontaneous MI rather than a false-negative FFR result.
The FFR results in the other patients with spontaneous MACE in
the FFR group did not influence the initial management of these
patients based on angiography alone implying the FFR strategy was
not associated with the MACE events. In the FAME trial, nearly
one-third of participants in the FAME trial had a history of recentMI.8
The potential for FFR disclosure to impact on physicians’ treat-
ment decisions in patients with recent unstable coronary disease is
also uncertain.19,30We found that FFR disclosure changed the treat-
ment plan in over one in five patients with a reduction in revascular-
ization on a patient basis. However, late spontaneous MACE tended
to be more common in the FFR-group, calling into question the
longer-term safety of an FFR-guided change from PCI to medical
therapy in culprit arteries. These observations place emphasis on
the need for a larger trial with a design that is informed by these
results and powered to definitively assess health outcomes and cost-
effectiveness.
The FAMOUS-NSTEMI trial differed from recent trials of FFR-
guided management (DEFER,7 FAME,8 FAME-2,9 and RIPCORD10)
in a number of important ways. Firstly, the primary diagnosis of the
patients differed between the trials. DEFER, FAME, and FAME-2
trials enrolled patients with stable coronary artery disease. In
FAME,8 NSTEMI patients were included within 5 days of the index
event provided the peak creatine kinase was ,1000 U per L. In
FAME-2,9 patients with Canadian Cardiovascular Society angina
class IV or an NSTEMI were only included if the symptoms had
been controlled for .7 days. Secondly, the treatment strategies in
these trials were not the same. In DEFER,7 FAME,8 and FAME-2,9 the
patients were selected for PCI, whereas FAMOUS patients were ran-
domizedupstreamat anearlier stage in the treatmentpathwaywhenall
treatment options were possible, including medical therapy, PCI and
CABG.Thirdly, theangiographic criteria forFFRmeasurementdiffered
between the trials. In the FAME trials, FFR was measured in stenoses
assessed visually to be at least intermediate (≥50% reference diam-
eter) in severity, whereas in FAMOUS even very mild narrowings
(≥30% reference diameter) were included. The characteristics of
the participants in the FAMOUS trial were similar to those of other
ACS trials, such as TIMACS35 (e.g. 80% of participants in both trials
had an ischaemic ECG). Finally, compared with standard care, health
outcomes were improved by FFR-guided management in the FAME
trials, whereas in FAMOUS, MI events were different and overall
MACE were similar at 12 months.
Balancing against the potential benefits, use of a diagnostic coron-
ary guidewire may come at the expense of cost and potential harm,
including procedure-related coronary dissections. In this study, two
coronary artery dissections were due to pressure wire instrumenta-
tion, as attributed by an independent clinical event committee which
reviewed the angiograms. In the RIPCORD study,10 in which all
coronaryarterieswere instrumented, threeclinically important com-
plications attributable to the pressurewire occurred in 200 patients.
In the angiography-guided group, the proportion of patients revas-
cularized at baseline (86.8%, Table 3)were lower than the proportion
ofpatientswith anangiographically significant stenosis (96.6%,Table 2).
In contrast, in the FFR-guided group, the proportionof patients with at
least one physiologically significant lesion (FFR ≤0.80; 80.7%, Table 2)
and the rate of revascularization at baseline (81.7%, Table 3) were
similar. In the sample size calculation (Supplementary material online,
Methods), we had anticipated a 15%difference inmedical management
between the randomized groups. The smaller actual difference (10.1%,
Table 3) could be in part be explained by the lower than expected rate
of revascularization in the angiographic control group.
The rate of change of the initial treatment plan in our trial was
lower than in other studies.7,8,10,30 This discrepancy is explained by
the lower rate of lesion re-classification by FFR disclosure in patients
with very mild (,50%) or very severe (.90%) lesions (Figure 3).
Lesions at the extremes of coronary stenosis severity were included
bydesign inorder to assess thediagnostic impactof FFRacross the full
range of stenosis severities. The relationship between lesion severity
and the health economic value of the FFR-guided strategy should
inform whether this strategy has more economic value within an
intermediate range of coronary stenosis severities (e.g. 50–90%).
The health economic implications of this trial will be assessed in a
future planned analysis.19
Limitations
The randomized participants in this trial were included because the
cardiologist believed coronary instrumentation with the pressure
wire was feasible, but this decision is subjective and some patients
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maynothavebeen includeddue tooperatorpreference. Even though
some features of severe coronary disease were exclusion criteria
(e.g. a severely calcified coronary artery), some patients with
severe coronary disease were still included supporting generalizabil-
ity of the trial findings. For example, 6.6% of the participants were re-
ferred forCABG;19%of theparticipants underwent angiographyfive
or more days from the index episode of myocardial ischaemia. This
time interval is explained by clinical service pressures that delayed
access to the catheter laboratory in some of the hospitals in this trial.
Most of the participants in our trial received clopidogrel whereas
ticagrelor, which improves cardiovascular outcomes in ACS patients
compared with clopidogrel,36 is now recommended in NSTEMI
patients.1 We have reported the cardiologists’ visual interpretation
of the angiogram as actually performed in the study participants. A
quantitative coronary analysis by blinded observers is currently
on-going.
Our study was designed (but not powered) to assess between-
group differences in health outcomes. There are too few cardiac
events to draw firm conclusions and the prognostic significance of
FFR-guided management in patients with optimal dual anti-platelet
therapy should be further assessed in a larger trial with longer-term
follow-up.
Conclusions
The FAMOUS-NSTEMI trial provides information on the feasibility,
safety, and clinical utility of a routine physiological approach to
guide the management of NSTEMI patients. We have shown that
comparedwith angiography-guided standard care, routine FFRmeas-
urement is feasible and safe, and FFRdisclosure resulted in a change in
treatment plan in more than one-fifth of patients and revasculariza-
tion was reduced overall. There were no differences in health out-
comes and quality of life between the randomized groups. In the
FFR group, procedure-relatedMI tended to be reduced but spontan-
eousMACEduring the follow-up tended to bemore commonduring
12-month follow-up. A large randomized trial is needed to definitive-
ly assess the cost-effectiveness of an FFR-guided management strat-
egy in invasively managed NSTEMI patients.
Supplementary material
Supplementary material is available at European Heart Journal online.
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